Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights

Core Insights - Tvardi Therapeutics, Inc. has reported positive preliminary results from its Phase 2 REVERT IPF clinical trial of TTI-101, showing a 9.4% decrease in fibrosis score at week 12 compared to a 2.4% decrease in the placebo group [1][6] - The company is also progressing with its next-generation STAT3 inhibitor, TTI-109, with topline data expected in H1 2026 [1][5] Group 1: Clinical Trial Results - In the REVERT IPF trial, TTI-101 demonstrated a significant reduction in fibrosis scores, with a baseline-weighted high-resolution CT lung fibrosis score showing a decline of 9.4% for TTI-101 versus 2.4% for placebo [6] - A greater decline in IL-6 levels was observed in patients treated with TTI-101, indicating effective STAT3 pathway inhibition [6] - 63% of patients treated with TTI-101 showed an increase in FVC at 12 weeks, compared to 46% in the placebo group, with mean FVC change being -15mL for TTI-101 versus -22mL for placebo [6] Group 2: Company Strategy and Future Directions - The CEO of Tvardi highlighted the encouraging results from the REVERT IPF trial and expressed eagerness for the upcoming results from the TTI-109 study, which aims to enhance the efficacy and tolerability of STAT3 targeting [4][5] - The REVERT IPF trial was a randomized, double-blind, placebo-controlled study designed to assess safety and exploratory outcomes related to lung function, although it did not meet its initial goals based on preliminary data [5]